Douglas Fish
Concepts (583)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Anti-Infective Agents | 19 | 2016 | 248 | 2.430 |
Why?
| Anti-Bacterial Agents | 28 | 2022 | 1562 | 2.000 |
Why?
| Vancomycin | 6 | 2024 | 81 | 1.490 |
Why?
| Staphylococcal Infections | 5 | 2022 | 348 | 1.400 |
Why?
| Surgical Wound Infection | 6 | 2016 | 251 | 1.220 |
Why?
| Sepsis | 7 | 2020 | 546 | 1.110 |
Why?
| Microbial Sensitivity Tests | 15 | 2022 | 312 | 1.100 |
Why?
| Endocarditis | 3 | 2024 | 36 | 1.070 |
Why?
| Critical Illness | 22 | 2022 | 728 | 1.000 |
Why?
| Antibiotic Prophylaxis | 7 | 2016 | 101 | 0.970 |
Why?
| Endocarditis, Bacterial | 1 | 2024 | 38 | 0.940 |
Why?
| Levofloxacin | 6 | 2006 | 22 | 0.930 |
Why?
| Ofloxacin | 6 | 2006 | 23 | 0.930 |
Why?
| Pseudomonas Infections | 5 | 2013 | 198 | 0.900 |
Why?
| Prodrugs | 4 | 2009 | 44 | 0.880 |
Why?
| Cephalexin | 1 | 2022 | 9 | 0.870 |
Why?
| Fluoroquinolones | 7 | 2007 | 43 | 0.870 |
Why?
| Bacterial Infections | 7 | 2009 | 234 | 0.820 |
Why?
| Hemofiltration | 8 | 2022 | 34 | 0.780 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 1 | 2024 | 240 | 0.780 |
Why?
| Cross Infection | 6 | 2011 | 218 | 0.760 |
Why?
| Intensive Care Units | 16 | 2016 | 664 | 0.760 |
Why?
| Renal Replacement Therapy | 4 | 2015 | 74 | 0.750 |
Why?
| Methicillin-Resistant Staphylococcus aureus | 3 | 2020 | 194 | 0.730 |
Why?
| Anticoagulants | 6 | 2016 | 589 | 0.720 |
Why?
| Heparin | 6 | 2016 | 240 | 0.710 |
Why?
| Education, Pharmacy | 2 | 2014 | 131 | 0.700 |
Why?
| Antiviral Agents | 6 | 2012 | 670 | 0.690 |
Why?
| Acute Kidney Injury | 4 | 2024 | 755 | 0.660 |
Why?
| Valine | 5 | 2008 | 79 | 0.630 |
Why?
| Vitreous Body | 2 | 2009 | 104 | 0.630 |
Why?
| beta-Lactams | 2 | 2020 | 29 | 0.620 |
Why?
| Acyclovir | 5 | 2008 | 104 | 0.620 |
Why?
| Critical Care | 11 | 2016 | 563 | 0.620 |
Why?
| Cefoxitin | 1 | 2016 | 11 | 0.590 |
Why?
| Humans | 122 | 2024 | 122796 | 0.570 |
Why?
| Obesity, Morbid | 2 | 2016 | 204 | 0.550 |
Why?
| Pseudomonas aeruginosa | 6 | 2013 | 310 | 0.550 |
Why?
| Middle Aged | 52 | 2024 | 28563 | 0.520 |
Why?
| Antifungal Agents | 6 | 2019 | 142 | 0.520 |
Why?
| Enterocolitis, Pseudomembranous | 1 | 2014 | 24 | 0.510 |
Why?
| Students, Pharmacy | 2 | 2014 | 102 | 0.510 |
Why?
| Drug Resistance, Microbial | 4 | 2006 | 71 | 0.500 |
Why?
| Pharmacy Service, Hospital | 3 | 2014 | 88 | 0.500 |
Why?
| Histamine H2 Antagonists | 1 | 2014 | 31 | 0.500 |
Why?
| Thrombocytopenia | 3 | 2009 | 188 | 0.500 |
Why?
| Problem-Based Learning | 2 | 2017 | 84 | 0.490 |
Why?
| Pneumonia | 4 | 2014 | 605 | 0.490 |
Why?
| Proton Pump Inhibitors | 1 | 2014 | 102 | 0.470 |
Why?
| Peritonitis | 2 | 2016 | 78 | 0.470 |
Why?
| Hirudins | 4 | 2010 | 49 | 0.460 |
Why?
| Hepatorenal Syndrome | 3 | 2013 | 14 | 0.460 |
Why?
| Pneumonia, Bacterial | 2 | 2013 | 113 | 0.450 |
Why?
| Voriconazole | 3 | 2019 | 26 | 0.450 |
Why?
| Community-Acquired Infections | 1 | 2014 | 148 | 0.450 |
Why?
| Colorectal Surgery | 1 | 2012 | 22 | 0.440 |
Why?
| Aged | 36 | 2024 | 20495 | 0.440 |
Why?
| Adult | 46 | 2024 | 32385 | 0.430 |
Why?
| Liver Cirrhosis | 3 | 2009 | 252 | 0.420 |
Why?
| Administration, Oral | 11 | 2019 | 786 | 0.420 |
Why?
| Teaching | 1 | 2014 | 241 | 0.410 |
Why?
| Male | 61 | 2024 | 59639 | 0.400 |
Why?
| Cephalosporins | 3 | 2012 | 30 | 0.400 |
Why?
| Burns | 3 | 2018 | 256 | 0.400 |
Why?
| Preoperative Care | 2 | 2012 | 342 | 0.390 |
Why?
| Enteral Nutrition | 4 | 2008 | 174 | 0.390 |
Why?
| Interpersonal Relations | 1 | 2014 | 351 | 0.390 |
Why?
| Drug Resistance, Multiple | 1 | 2010 | 19 | 0.380 |
Why?
| Cefazolin | 2 | 2022 | 20 | 0.380 |
Why?
| Imipenem | 3 | 2010 | 18 | 0.380 |
Why?
| Staphylococcus aureus | 3 | 2022 | 400 | 0.380 |
Why?
| Chromatography, High Pressure Liquid | 9 | 2012 | 493 | 0.370 |
Why?
| Syringes | 2 | 2007 | 40 | 0.370 |
Why?
| Penicillanic Acid | 2 | 2013 | 4 | 0.370 |
Why?
| Female | 58 | 2024 | 63629 | 0.370 |
Why?
| Dexmedetomidine | 3 | 2014 | 58 | 0.350 |
Why?
| 2-Aminopurine | 1 | 2009 | 10 | 0.350 |
Why?
| HIV Protease Inhibitors | 2 | 2000 | 65 | 0.350 |
Why?
| Peptide Fragments | 3 | 2010 | 715 | 0.340 |
Why?
| Retrospective Studies | 23 | 2024 | 13433 | 0.340 |
Why?
| Peptic Ulcer | 2 | 2014 | 15 | 0.330 |
Why?
| Recombinant Proteins | 6 | 2010 | 1318 | 0.330 |
Why?
| Monte Carlo Method | 3 | 2016 | 149 | 0.320 |
Why?
| Drug Delivery Systems | 2 | 2006 | 312 | 0.310 |
Why?
| Protein C | 2 | 2010 | 44 | 0.310 |
Why?
| Infection Control | 3 | 2010 | 138 | 0.310 |
Why?
| Polypropylenes | 1 | 2007 | 19 | 0.310 |
Why?
| Drug Monitoring | 6 | 2017 | 189 | 0.310 |
Why?
| Sympathomimetics | 1 | 2007 | 26 | 0.300 |
Why?
| Phenylephrine | 1 | 2007 | 85 | 0.300 |
Why?
| Expectorants | 1 | 2007 | 23 | 0.300 |
Why?
| Hypnotics and Sedatives | 3 | 2014 | 146 | 0.300 |
Why?
| Triazoles | 2 | 2019 | 135 | 0.300 |
Why?
| Clarithromycin | 2 | 1999 | 29 | 0.300 |
Why?
| Aged, 80 and over | 15 | 2018 | 6845 | 0.300 |
Why?
| Accreditation | 1 | 2007 | 96 | 0.300 |
Why?
| Community Pharmacy Services | 1 | 2007 | 47 | 0.300 |
Why?
| Drug Packaging | 1 | 2007 | 45 | 0.290 |
Why?
| Educational Measurement | 3 | 2017 | 298 | 0.280 |
Why?
| Acetylcysteine | 1 | 2007 | 150 | 0.280 |
Why?
| Pipecolic Acids | 1 | 2005 | 22 | 0.280 |
Why?
| Piperacillin | 2 | 2013 | 10 | 0.280 |
Why?
| Penicillins | 2 | 2004 | 51 | 0.270 |
Why?
| Drug Interactions | 6 | 2013 | 356 | 0.270 |
Why?
| Ketolides | 1 | 2005 | 1 | 0.270 |
Why?
| Models, Biological | 1 | 2013 | 1756 | 0.270 |
Why?
| Nursing Homes | 3 | 2011 | 137 | 0.260 |
Why?
| Thrombin | 1 | 2006 | 140 | 0.260 |
Why?
| Prospective Studies | 15 | 2018 | 6704 | 0.260 |
Why?
| Kidney Diseases | 3 | 2009 | 446 | 0.260 |
Why?
| Bacteria | 4 | 2022 | 772 | 0.260 |
Why?
| HIV Infections | 6 | 2013 | 2532 | 0.250 |
Why?
| Bacteremia | 3 | 2018 | 169 | 0.250 |
Why?
| Enterobacter cloacae | 1 | 2004 | 3 | 0.250 |
Why?
| Aza Compounds | 1 | 2004 | 12 | 0.250 |
Why?
| Acinetobacter baumannii | 1 | 2004 | 16 | 0.250 |
Why?
| Respiratory Tract Infections | 2 | 2005 | 335 | 0.240 |
Why?
| Klebsiella pneumoniae | 1 | 2004 | 42 | 0.240 |
Why?
| Anticonvulsants | 2 | 2017 | 189 | 0.240 |
Why?
| Severity of Illness Index | 2 | 2013 | 2784 | 0.230 |
Why?
| Drug Storage | 4 | 2007 | 61 | 0.230 |
Why?
| Area Under Curve | 6 | 2008 | 303 | 0.230 |
Why?
| Half-Life | 5 | 2012 | 147 | 0.230 |
Why?
| Obesity | 1 | 2016 | 2786 | 0.230 |
Why?
| Drug Stability | 4 | 2007 | 157 | 0.230 |
Why?
| Quinolines | 1 | 2004 | 127 | 0.230 |
Why?
| Liver Diseases | 1 | 2006 | 325 | 0.220 |
Why?
| AIDS-Related Opportunistic Infections | 2 | 1993 | 114 | 0.220 |
Why?
| Tissue Distribution | 3 | 2016 | 339 | 0.220 |
Why?
| Cefadroxil | 1 | 2022 | 7 | 0.220 |
Why?
| Cephalothin | 1 | 2022 | 7 | 0.220 |
Why?
| Oxacillin | 1 | 2022 | 8 | 0.220 |
Why?
| Methicillin | 1 | 2022 | 12 | 0.220 |
Why?
| Dose-Response Relationship, Drug | 5 | 2016 | 1981 | 0.220 |
Why?
| Anti-HIV Agents | 2 | 1999 | 685 | 0.210 |
Why?
| Infusions, Intravenous | 7 | 2016 | 396 | 0.210 |
Why?
| Quinolones | 1 | 2003 | 97 | 0.210 |
Why?
| Drug Therapy, Combination | 8 | 2016 | 988 | 0.210 |
Why?
| Lorazepam | 2 | 2014 | 26 | 0.210 |
Why?
| Bronchi | 1 | 2003 | 253 | 0.210 |
Why?
| Antacids | 1 | 2001 | 15 | 0.210 |
Why?
| Substance Withdrawal Syndrome | 2 | 2014 | 159 | 0.210 |
Why?
| Bronchoscopy | 1 | 2003 | 254 | 0.210 |
Why?
| Kidney Failure, Chronic | 5 | 2016 | 519 | 0.210 |
Why?
| Catheters, Indwelling | 2 | 2016 | 82 | 0.210 |
Why?
| Liver Transplantation | 1 | 2009 | 929 | 0.200 |
Why?
| Hemodiafiltration | 2 | 2005 | 10 | 0.200 |
Why?
| Ciprofloxacin | 3 | 2004 | 24 | 0.200 |
Why?
| Colorado | 12 | 2021 | 4325 | 0.200 |
Why?
| Fibrinolytic Agents | 2 | 2016 | 257 | 0.190 |
Why?
| Antidiarrheals | 1 | 2000 | 14 | 0.190 |
Why?
| Fludrocortisone | 1 | 2000 | 3 | 0.190 |
Why?
| Mineralocorticoids | 1 | 2000 | 3 | 0.190 |
Why?
| Lung Transplantation | 2 | 2014 | 273 | 0.190 |
Why?
| Naphthyridines | 1 | 2000 | 16 | 0.190 |
Why?
| Octreotide | 2 | 2013 | 27 | 0.190 |
Why?
| Public Health Administration | 1 | 2021 | 81 | 0.190 |
Why?
| Enzyme Inhibitors | 1 | 2004 | 836 | 0.180 |
Why?
| Clinical Competence | 1 | 2007 | 973 | 0.180 |
Why?
| Hyperkalemia | 1 | 2000 | 28 | 0.180 |
Why?
| Multivariate Analysis | 6 | 2017 | 1531 | 0.180 |
Why?
| Ethanol | 2 | 2014 | 584 | 0.180 |
Why?
| Multiple Organ Failure | 2 | 2010 | 166 | 0.180 |
Why?
| Extracorporeal Membrane Oxygenation | 1 | 2022 | 249 | 0.180 |
Why?
| Thienamycins | 2 | 2005 | 4 | 0.170 |
Why?
| Invasive Fungal Infections | 1 | 2019 | 12 | 0.170 |
Why?
| Cytosine | 1 | 1999 | 46 | 0.170 |
Why?
| Diarrhea | 1 | 2000 | 181 | 0.170 |
Why?
| Practice Guidelines as Topic | 5 | 2016 | 1519 | 0.170 |
Why?
| Hydroxyurea | 1 | 1999 | 32 | 0.170 |
Why?
| Nafcillin | 1 | 2018 | 4 | 0.170 |
Why?
| Clostridium Infections | 1 | 2019 | 61 | 0.170 |
Why?
| APACHE | 3 | 2010 | 65 | 0.170 |
Why?
| Organophosphonates | 1 | 1999 | 96 | 0.160 |
Why?
| Schools, Pharmacy | 2 | 2017 | 53 | 0.160 |
Why?
| Organophosphorus Compounds | 1 | 1999 | 78 | 0.160 |
Why?
| Reverse Transcriptase Inhibitors | 1 | 1998 | 85 | 0.160 |
Why?
| Nitriles | 1 | 2019 | 158 | 0.160 |
Why?
| Cohort Studies | 7 | 2013 | 5294 | 0.160 |
Why?
| Vitrectomy | 2 | 2009 | 58 | 0.160 |
Why?
| Transplantation Conditioning | 1 | 2019 | 158 | 0.160 |
Why?
| Communicable Diseases | 1 | 2020 | 135 | 0.160 |
Why?
| Gastric Emptying | 2 | 2008 | 40 | 0.160 |
Why?
| Neuromuscular Nondepolarizing Agents | 1 | 1997 | 9 | 0.160 |
Why?
| Vecuronium Bromide | 1 | 1997 | 6 | 0.160 |
Why?
| Atracurium | 1 | 1997 | 13 | 0.160 |
Why?
| Pharmaceutical Services | 1 | 1998 | 80 | 0.160 |
Why?
| Lyme Disease | 3 | 2000 | 32 | 0.160 |
Why?
| Sumatriptan | 1 | 1997 | 6 | 0.160 |
Why?
| Bites and Stings | 3 | 2000 | 32 | 0.160 |
Why?
| Hematologic Neoplasms | 1 | 2019 | 135 | 0.160 |
Why?
| Gastrointestinal Agents | 2 | 2008 | 61 | 0.160 |
Why?
| Serotonin Receptor Agonists | 1 | 1997 | 28 | 0.150 |
Why?
| Treatment Outcome | 10 | 2018 | 9692 | 0.150 |
Why?
| Cardiopulmonary Bypass | 2 | 2016 | 213 | 0.150 |
Why?
| Antibodies, Bacterial | 1 | 2018 | 129 | 0.150 |
Why?
| Piracetam | 1 | 2017 | 16 | 0.150 |
Why?
| Immunity, Humoral | 1 | 2018 | 116 | 0.150 |
Why?
| Education, Pharmacy, Graduate | 1 | 2017 | 23 | 0.150 |
Why?
| Vasodilator Agents | 2 | 2016 | 339 | 0.150 |
Why?
| Hydrogen-Ion Concentration | 4 | 2014 | 547 | 0.150 |
Why?
| Drug Administration Schedule | 5 | 2018 | 757 | 0.150 |
Why?
| Neurosurgical Procedures | 1 | 2018 | 165 | 0.140 |
Why?
| Pneumococcal Vaccines | 1 | 2018 | 141 | 0.140 |
Why?
| Intracranial Hemorrhages | 1 | 2017 | 77 | 0.140 |
Why?
| Pneumonectomy | 1 | 1998 | 123 | 0.140 |
Why?
| Thiocyanates | 1 | 2016 | 31 | 0.140 |
Why?
| Nitroprusside | 1 | 2016 | 90 | 0.140 |
Why?
| Administration, Intravenous | 2 | 2017 | 152 | 0.140 |
Why?
| Drug Resistance, Multiple, Bacterial | 3 | 2005 | 66 | 0.140 |
Why?
| Benzodiazepines | 2 | 2014 | 125 | 0.140 |
Why?
| Thiosulfates | 1 | 2016 | 23 | 0.140 |
Why?
| Toxoplasmosis, Cerebral | 1 | 1995 | 2 | 0.140 |
Why?
| Partial Thromboplastin Time | 2 | 2006 | 52 | 0.140 |
Why?
| Naphthoquinones | 1 | 1995 | 18 | 0.140 |
Why?
| Famotidine | 1 | 1995 | 2 | 0.140 |
Why?
| Antiprotozoal Agents | 1 | 1995 | 12 | 0.140 |
Why?
| Pneumonia, Pneumocystis | 1 | 1995 | 32 | 0.140 |
Why?
| Gram-Positive Bacterial Infections | 2 | 1997 | 70 | 0.130 |
Why?
| Pyridines | 1 | 2019 | 440 | 0.130 |
Why?
| Drug Resistance | 2 | 2011 | 169 | 0.130 |
Why?
| Therapeutics | 1 | 2015 | 12 | 0.130 |
Why?
| Peptic Ulcer Hemorrhage | 1 | 2014 | 6 | 0.130 |
Why?
| Drug Utilization Review | 1 | 1995 | 65 | 0.130 |
Why?
| Peritoneal Dialysis | 1 | 2016 | 86 | 0.130 |
Why?
| Academic Medical Centers | 2 | 2019 | 427 | 0.130 |
Why?
| beta-Cyclodextrins | 1 | 2015 | 32 | 0.130 |
Why?
| Anti-Ulcer Agents | 1 | 2014 | 17 | 0.130 |
Why?
| Body Weight | 2 | 2016 | 958 | 0.130 |
Why?
| Diltiazem | 1 | 2014 | 22 | 0.120 |
Why?
| Temperature | 2 | 2007 | 631 | 0.120 |
Why?
| Antidotes | 1 | 2016 | 160 | 0.120 |
Why?
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2014 | 17 | 0.120 |
Why?
| Drug Dosage Calculations | 1 | 2014 | 21 | 0.120 |
Why?
| Osmotic Pressure | 1 | 2014 | 33 | 0.120 |
Why?
| Vasopressins | 2 | 2004 | 64 | 0.120 |
Why?
| Mass Casualty Incidents | 1 | 2014 | 42 | 0.120 |
Why?
| Biopsy | 1 | 1998 | 1090 | 0.120 |
Why?
| Biological Availability | 4 | 2009 | 129 | 0.120 |
Why?
| Immunoglobulin G | 1 | 2018 | 804 | 0.120 |
Why?
| Somatostatin | 1 | 2013 | 54 | 0.120 |
Why?
| Vasoconstrictor Agents | 2 | 2004 | 128 | 0.120 |
Why?
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 543 | 0.120 |
Why?
| Homicide | 1 | 2014 | 51 | 0.120 |
Why?
| Gastrointestinal Hemorrhage | 1 | 2014 | 113 | 0.120 |
Why?
| Midazolam | 1 | 2013 | 51 | 0.120 |
Why?
| Infectious Disease Transmission, Patient-to-Professional | 1 | 1993 | 22 | 0.120 |
Why?
| Zidovudine | 1 | 1993 | 78 | 0.120 |
Why?
| Injections, Intravenous | 4 | 2012 | 217 | 0.120 |
Why?
| Stress, Psychological | 1 | 2001 | 1021 | 0.110 |
Why?
| Nursing Staff | 2 | 2010 | 41 | 0.110 |
Why?
| Ticks | 2 | 1993 | 12 | 0.110 |
Why?
| Bacteroides fragilis | 1 | 2012 | 10 | 0.110 |
Why?
| Risk Factors | 9 | 2014 | 9381 | 0.110 |
Why?
| Conscious Sedation | 1 | 2013 | 84 | 0.110 |
Why?
| Lung | 2 | 1998 | 3830 | 0.110 |
Why?
| Sirolimus | 1 | 2014 | 198 | 0.110 |
Why?
| Telemedicine | 1 | 2021 | 691 | 0.110 |
Why?
| Bone Cements | 1 | 1992 | 39 | 0.110 |
Why?
| Transplant Recipients | 1 | 2014 | 149 | 0.110 |
Why?
| Program Evaluation | 1 | 2017 | 880 | 0.110 |
Why?
| Renal Dialysis | 3 | 2022 | 395 | 0.110 |
Why?
| Vasoconstriction | 1 | 2014 | 216 | 0.110 |
Why?
| Mental Recall | 1 | 2013 | 185 | 0.110 |
Why?
| Coronary Artery Bypass | 1 | 2014 | 226 | 0.110 |
Why?
| Comprehension | 1 | 2014 | 169 | 0.110 |
Why?
| Acquired Immunodeficiency Syndrome | 1 | 1993 | 222 | 0.110 |
Why?
| Enterococcus | 1 | 1992 | 19 | 0.110 |
Why?
| Long QT Syndrome | 1 | 2013 | 59 | 0.110 |
Why?
| Ganciclovir | 1 | 2012 | 46 | 0.110 |
Why?
| Treatment Failure | 1 | 2013 | 348 | 0.110 |
Why?
| Shock, Septic | 2 | 2004 | 213 | 0.100 |
Why?
| Clinical Trials as Topic | 4 | 2000 | 985 | 0.100 |
Why?
| Creatinine | 2 | 2007 | 510 | 0.100 |
Why?
| Occupational Diseases | 1 | 1993 | 143 | 0.100 |
Why?
| Educational Status | 1 | 2014 | 448 | 0.100 |
Why?
| Metoclopramide | 2 | 2008 | 18 | 0.100 |
Why?
| Erythromycin | 2 | 2008 | 26 | 0.100 |
Why?
| Drug Resistance, Multiple, Fungal | 1 | 2011 | 1 | 0.100 |
Why?
| Metabolic Clearance Rate | 4 | 2012 | 111 | 0.100 |
Why?
| Candida | 1 | 2011 | 36 | 0.100 |
Why?
| Traction | 1 | 1991 | 17 | 0.100 |
Why?
| Curriculum | 2 | 2017 | 925 | 0.100 |
Why?
| Heart Valve Prosthesis Implantation | 1 | 2014 | 191 | 0.100 |
Why?
| Anti-Anxiety Agents | 1 | 1991 | 41 | 0.100 |
Why?
| Candidiasis | 1 | 2011 | 59 | 0.100 |
Why?
| Wounds, Gunshot | 1 | 2014 | 178 | 0.100 |
Why?
| Neuromuscular Blocking Agents | 1 | 2011 | 24 | 0.100 |
Why?
| Neuromuscular Blockade | 1 | 2011 | 24 | 0.100 |
Why?
| Suspensions | 3 | 2002 | 30 | 0.100 |
Why?
| Practice Patterns, Physicians' | 3 | 2014 | 1267 | 0.100 |
Why?
| Hip Dislocation, Congenital | 1 | 1991 | 39 | 0.100 |
Why?
| Primary Health Care | 1 | 2021 | 1625 | 0.100 |
Why?
| Genes, Regulator | 1 | 2010 | 33 | 0.090 |
Why?
| Polymorphism, Genetic | 1 | 2014 | 666 | 0.090 |
Why?
| Adolescent | 12 | 2018 | 18948 | 0.090 |
Why?
| Vancomycin Resistance | 1 | 2010 | 16 | 0.090 |
Why?
| Delirium | 1 | 1991 | 72 | 0.090 |
Why?
| Clinical Trials, Phase III as Topic | 2 | 2002 | 75 | 0.090 |
Why?
| Recurrence | 2 | 2009 | 998 | 0.090 |
Why?
| Hypothermia, Induced | 1 | 2011 | 69 | 0.090 |
Why?
| Pharmaceutical Vehicles | 1 | 2009 | 13 | 0.090 |
Why?
| Propylene Glycol | 1 | 2009 | 9 | 0.090 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 2010 | 336 | 0.090 |
Why?
| Cytomegalovirus Infections | 1 | 2012 | 188 | 0.090 |
Why?
| Retinal Necrosis Syndrome, Acute | 1 | 2009 | 9 | 0.090 |
Why?
| Eye Infections, Viral | 1 | 2009 | 7 | 0.090 |
Why?
| Aortic Valve | 1 | 2014 | 428 | 0.090 |
Why?
| Electrocardiography | 1 | 2013 | 620 | 0.090 |
Why?
| Guideline Adherence | 2 | 2011 | 560 | 0.090 |
Why?
| Sensitivity and Specificity | 2 | 2013 | 1855 | 0.090 |
Why?
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2009 | 42 | 0.090 |
Why?
| Antipsychotic Agents | 1 | 1991 | 197 | 0.090 |
Why?
| Tick Infestations | 1 | 1988 | 4 | 0.090 |
Why?
| Education, Continuing | 1 | 2009 | 42 | 0.090 |
Why?
| Double-Blind Method | 5 | 2014 | 1711 | 0.090 |
Why?
| Young Adult | 5 | 2019 | 11094 | 0.080 |
Why?
| Regression Analysis | 4 | 2016 | 1018 | 0.080 |
Why?
| Patients | 1 | 2010 | 176 | 0.080 |
Why?
| Models, Statistical | 1 | 2012 | 651 | 0.080 |
Why?
| Escherichia coli | 1 | 2012 | 767 | 0.080 |
Why?
| Immunization Programs | 1 | 2010 | 210 | 0.080 |
Why?
| Communication | 1 | 2014 | 776 | 0.080 |
Why?
| Acetaminophen | 2 | 2008 | 261 | 0.080 |
Why?
| Antitubercular Agents | 2 | 1999 | 167 | 0.080 |
Why?
| Pharmacists | 3 | 2020 | 245 | 0.080 |
Why?
| Time Factors | 7 | 2014 | 6682 | 0.080 |
Why?
| Health Personnel | 1 | 1993 | 603 | 0.080 |
Why?
| Cost Control | 1 | 2007 | 46 | 0.080 |
Why?
| Lung Diseases | 1 | 2014 | 764 | 0.070 |
Why?
| Chronic Disease | 1 | 2013 | 1645 | 0.070 |
Why?
| Incidence | 3 | 2006 | 2527 | 0.070 |
Why?
| Cerebrospinal Fluid Shunts | 1 | 2007 | 31 | 0.070 |
Why?
| Glutamine | 1 | 2007 | 89 | 0.070 |
Why?
| Cerebrospinal Fluid | 1 | 2007 | 92 | 0.070 |
Why?
| Analgesics, Non-Narcotic | 1 | 2008 | 122 | 0.070 |
Why?
| Peripheral Blood Stem Cell Transplantation | 1 | 2006 | 19 | 0.070 |
Why?
| Preceptorship | 1 | 2006 | 63 | 0.070 |
Why?
| Child | 4 | 2022 | 19561 | 0.070 |
Why?
| Granulocyte Colony-Stimulating Factor | 1 | 2006 | 70 | 0.070 |
Why?
| Drug Costs | 2 | 1999 | 100 | 0.070 |
Why?
| Cilastatin | 1 | 2005 | 3 | 0.070 |
Why?
| Platelet Activation | 1 | 2005 | 71 | 0.070 |
Why?
| Arginine Vasopressin | 1 | 2005 | 47 | 0.070 |
Why?
| United States | 6 | 2014 | 13272 | 0.070 |
Why?
| Platelet Aggregation | 1 | 2005 | 98 | 0.070 |
Why?
| Chromatography, Liquid | 1 | 2007 | 356 | 0.070 |
Why?
| Cyclosporine | 2 | 2006 | 175 | 0.070 |
Why?
| Central Nervous System | 1 | 2007 | 244 | 0.060 |
Why?
| Protease Inhibitors | 1 | 2005 | 106 | 0.060 |
Why?
| Arginine | 1 | 2005 | 254 | 0.060 |
Why?
| Case-Control Studies | 2 | 2014 | 3296 | 0.060 |
Why?
| Acinetobacter Infections | 1 | 2004 | 10 | 0.060 |
Why?
| Intubation, Gastrointestinal | 2 | 2008 | 61 | 0.060 |
Why?
| Gene Expression Regulation | 1 | 2014 | 2491 | 0.060 |
Why?
| Statistics, Nonparametric | 2 | 2016 | 416 | 0.060 |
Why?
| Klebsiella Infections | 1 | 2004 | 25 | 0.060 |
Why?
| Influenza, Human | 1 | 2010 | 566 | 0.060 |
Why?
| Immunosuppressive Agents | 2 | 2014 | 687 | 0.060 |
Why?
| Colony Count, Microbial | 1 | 2004 | 124 | 0.060 |
Why?
| Enterobacteriaceae Infections | 1 | 2004 | 34 | 0.060 |
Why?
| Intensive Care Units, Neonatal | 1 | 2006 | 184 | 0.060 |
Why?
| Surveys and Questionnaires | 5 | 2014 | 4882 | 0.060 |
Why?
| Graft vs Host Disease | 1 | 2006 | 219 | 0.060 |
Why?
| Staphylococcal Skin Infections | 1 | 2003 | 30 | 0.060 |
Why?
| Animals | 9 | 2014 | 34133 | 0.060 |
Why?
| DNA | 1 | 2010 | 1401 | 0.060 |
Why?
| Drug Synergism | 1 | 2004 | 346 | 0.060 |
Why?
| Kidney Transplantation | 1 | 2009 | 584 | 0.060 |
Why?
| Gestational Age | 1 | 2006 | 787 | 0.060 |
Why?
| Clinical Trials, Phase II as Topic | 1 | 2002 | 58 | 0.060 |
Why?
| Cross-Sectional Studies | 4 | 2014 | 4734 | 0.060 |
Why?
| Hematopoietic Stem Cells | 1 | 2006 | 370 | 0.050 |
Why?
| Kidney Function Tests | 1 | 2003 | 166 | 0.050 |
Why?
| Sulfonamides | 1 | 2005 | 455 | 0.050 |
Why?
| Clinical Protocols | 2 | 1995 | 248 | 0.050 |
Why?
| Infant, Premature | 1 | 2006 | 507 | 0.050 |
Why?
| Transcription Factors | 1 | 2010 | 1616 | 0.050 |
Why?
| Respiration, Artificial | 2 | 2014 | 596 | 0.050 |
Why?
| Computer Simulation | 1 | 2006 | 945 | 0.050 |
Why?
| Kansas | 2 | 2011 | 30 | 0.050 |
Why?
| Osmolar Concentration | 2 | 2002 | 185 | 0.050 |
Why?
| Iridium Radioisotopes | 1 | 2001 | 6 | 0.050 |
Why?
| Missouri | 2 | 2011 | 65 | 0.050 |
Why?
| Hospitalization | 1 | 2010 | 1914 | 0.050 |
Why?
| Pharmacokinetics | 1 | 2001 | 25 | 0.050 |
Why?
| Epstein-Barr Virus Infections | 1 | 2002 | 73 | 0.050 |
Why?
| Azithromycin | 1 | 2001 | 94 | 0.050 |
Why?
| Arachnid Vectors | 1 | 2000 | 3 | 0.050 |
Why?
| Borrelia burgdorferi Group | 1 | 2000 | 8 | 0.050 |
Why?
| Randomized Controlled Trials as Topic | 2 | 2004 | 1260 | 0.050 |
Why?
| Ixodes | 1 | 2000 | 11 | 0.050 |
Why?
| Milk, Human | 1 | 2002 | 149 | 0.050 |
Why?
| Aldosterone | 1 | 2000 | 45 | 0.050 |
Why?
| Surgical Procedures, Operative | 2 | 2013 | 227 | 0.050 |
Why?
| Infant, Newborn | 3 | 2007 | 5430 | 0.050 |
Why?
| Brachytherapy | 1 | 2001 | 103 | 0.050 |
Why?
| Ethionamide | 1 | 1999 | 1 | 0.050 |
Why?
| Aminosalicylic Acid | 1 | 1999 | 1 | 0.050 |
Why?
| Health Plan Implementation | 1 | 2021 | 132 | 0.050 |
Why?
| Cycloserine | 1 | 1999 | 3 | 0.050 |
Why?
| Aspartate Aminotransferases | 1 | 2000 | 96 | 0.050 |
Why?
| Pneumonia, Pneumococcal | 1 | 2000 | 42 | 0.050 |
Why?
| Clofazimine | 1 | 1999 | 15 | 0.040 |
Why?
| Potassium | 1 | 2000 | 150 | 0.040 |
Why?
| Pyrazinamide | 1 | 1999 | 8 | 0.040 |
Why?
| Hydroxylation | 1 | 1999 | 25 | 0.040 |
Why?
| Mutation | 1 | 2010 | 3493 | 0.040 |
Why?
| Renal Insufficiency | 1 | 2001 | 154 | 0.040 |
Why?
| Alanine Transaminase | 1 | 2000 | 152 | 0.040 |
Why?
| Ethambutol | 1 | 1999 | 20 | 0.040 |
Why?
| Antibiotics, Antitubercular | 1 | 1999 | 35 | 0.040 |
Why?
| Postpartum Period | 1 | 2002 | 281 | 0.040 |
Why?
| Drug Combinations | 1 | 2000 | 292 | 0.040 |
Why?
| Virus Activation | 1 | 1999 | 80 | 0.040 |
Why?
| Molecular Structure | 1 | 2000 | 463 | 0.040 |
Why?
| Isoniazid | 1 | 1999 | 55 | 0.040 |
Why?
| Cornea | 1 | 1999 | 120 | 0.040 |
Why?
| Rifampin | 1 | 1999 | 71 | 0.040 |
Why?
| Age Factors | 3 | 2013 | 3114 | 0.040 |
Why?
| Herpesvirus 1, Human | 1 | 1999 | 82 | 0.040 |
Why?
| Eye | 1 | 1999 | 108 | 0.040 |
Why?
| Vascular Grafting | 1 | 2018 | 13 | 0.040 |
Why?
| Length of Stay | 3 | 2014 | 1077 | 0.040 |
Why?
| Laser Therapy | 1 | 1999 | 105 | 0.040 |
Why?
| CD4 Lymphocyte Count | 1 | 1999 | 274 | 0.040 |
Why?
| Venous Thrombosis | 1 | 2000 | 148 | 0.040 |
Why?
| Drug Resistance, Viral | 1 | 1999 | 99 | 0.040 |
Why?
| Coronary Disease | 1 | 2001 | 372 | 0.040 |
Why?
| Spectrophotometry, Ultraviolet | 2 | 2012 | 76 | 0.040 |
Why?
| Cross Reactions | 1 | 1997 | 118 | 0.040 |
Why?
| Nausea | 1 | 1998 | 110 | 0.040 |
Why?
| Risk Assessment | 3 | 2016 | 3213 | 0.040 |
Why?
| Drug Compounding | 1 | 2017 | 92 | 0.040 |
Why?
| Stents | 1 | 2001 | 491 | 0.040 |
Why?
| Prognosis | 2 | 2016 | 3563 | 0.040 |
Why?
| Meningitis, Bacterial | 1 | 1997 | 50 | 0.040 |
Why?
| Gram-Negative Bacterial Infections | 1 | 1997 | 39 | 0.040 |
Why?
| Migraine Disorders | 1 | 1997 | 81 | 0.040 |
Why?
| Public Health | 1 | 2021 | 480 | 0.040 |
Why?
| Hip Prosthesis | 1 | 1996 | 35 | 0.030 |
Why?
| Atovaquone | 1 | 1995 | 2 | 0.030 |
Why?
| Particle Size | 1 | 1997 | 344 | 0.030 |
Why?
| Cross-Over Studies | 2 | 2012 | 469 | 0.030 |
Why?
| Respiratory Function Tests | 1 | 1997 | 563 | 0.030 |
Why?
| Appendicitis | 1 | 1997 | 128 | 0.030 |
Why?
| Aminoglycosides | 1 | 1995 | 15 | 0.030 |
Why?
| Catheterization | 1 | 2016 | 165 | 0.030 |
Why?
| Internationality | 1 | 2016 | 158 | 0.030 |
Why?
| Kidney | 1 | 2003 | 1355 | 0.030 |
Why?
| Costs and Cost Analysis | 1 | 1995 | 211 | 0.030 |
Why?
| Cytochrome P-450 CYP2C8 | 1 | 2014 | 15 | 0.030 |
Why?
| Liver Failure | 1 | 1995 | 94 | 0.030 |
Why?
| Infusions, Parenteral | 1 | 2014 | 38 | 0.030 |
Why?
| Standard of Care | 1 | 2014 | 67 | 0.030 |
Why?
| Bradycardia | 1 | 2014 | 58 | 0.030 |
Why?
| Aryl Hydrocarbon Hydroxylases | 1 | 2014 | 43 | 0.030 |
Why?
| Everolimus | 1 | 2014 | 64 | 0.030 |
Why?
| Stress Disorders, Traumatic, Acute | 1 | 2013 | 9 | 0.030 |
Why?
| Primary Prevention | 1 | 2016 | 212 | 0.030 |
Why?
| Receptors, Steroid | 1 | 2014 | 54 | 0.030 |
Why?
| Seizures | 1 | 2017 | 360 | 0.030 |
Why?
| Cytochrome P-450 CYP3A | 1 | 2014 | 60 | 0.030 |
Why?
| Haemophilus Infections | 1 | 1993 | 32 | 0.030 |
Why?
| Nutritional Status | 1 | 1996 | 306 | 0.030 |
Why?
| Esophageal and Gastric Varices | 1 | 2013 | 41 | 0.030 |
Why?
| Safety | 1 | 1995 | 307 | 0.030 |
Why?
| Pleural Effusion | 1 | 2013 | 53 | 0.030 |
Why?
| Chemotherapy, Adjuvant | 1 | 2014 | 369 | 0.030 |
Why?
| Demography | 1 | 2014 | 290 | 0.030 |
Why?
| Child, Preschool | 4 | 2007 | 9755 | 0.030 |
Why?
| Torsades de Pointes | 1 | 2013 | 22 | 0.030 |
Why?
| Disaster Planning | 1 | 2014 | 77 | 0.030 |
Why?
| Hypotension | 1 | 2014 | 135 | 0.030 |
Why?
| Salmonella Infections | 1 | 1993 | 51 | 0.030 |
Why?
| Methylmethacrylates | 1 | 1992 | 4 | 0.030 |
Why?
| Rats | 1 | 2001 | 5426 | 0.030 |
Why?
| Medical Audit | 1 | 2013 | 78 | 0.030 |
Why?
| New York | 2 | 1993 | 121 | 0.030 |
Why?
| Pneumococcal Infections | 1 | 1993 | 99 | 0.030 |
Why?
| 4-Quinolones | 1 | 1992 | 1 | 0.030 |
Why?
| Pandemics | 1 | 2021 | 1401 | 0.030 |
Why?
| Health Care Surveys | 1 | 2014 | 564 | 0.030 |
Why?
| Arthroplasty | 1 | 1992 | 53 | 0.030 |
Why?
| Kidney Tubular Necrosis, Acute | 1 | 2012 | 25 | 0.030 |
Why?
| Logistic Models | 1 | 2017 | 1995 | 0.030 |
Why?
| Societies, Medical | 1 | 2016 | 741 | 0.030 |
Why?
| Barbiturates | 1 | 1991 | 5 | 0.030 |
Why?
| Survival Rate | 1 | 2016 | 1810 | 0.030 |
Why?
| Immunocompromised Host | 1 | 1993 | 205 | 0.030 |
Why?
| Shock, Cardiogenic | 1 | 2012 | 62 | 0.030 |
Why?
| Education, Nursing, Continuing | 1 | 2011 | 42 | 0.030 |
Why?
| Hepacivirus | 1 | 2013 | 234 | 0.020 |
Why?
| Patient Education as Topic | 1 | 2016 | 717 | 0.020 |
Why?
| Infant | 3 | 2007 | 8523 | 0.020 |
Why?
| Stress, Physiological | 1 | 2014 | 433 | 0.020 |
Why?
| Midwestern United States | 1 | 2010 | 40 | 0.020 |
Why?
| Decision Trees | 1 | 2010 | 95 | 0.020 |
Why?
| Antibodies | 1 | 1993 | 400 | 0.020 |
Why?
| Antithrombins | 1 | 2010 | 57 | 0.020 |
Why?
| Occupational Exposure | 1 | 1993 | 298 | 0.020 |
Why?
| Gastroesophageal Reflux | 1 | 2013 | 252 | 0.020 |
Why?
| Professional Role | 1 | 2011 | 162 | 0.020 |
Why?
| Hospitals | 1 | 1995 | 633 | 0.020 |
Why?
| Contraindications | 1 | 2010 | 102 | 0.020 |
Why?
| Canada | 1 | 1991 | 355 | 0.020 |
Why?
| United Kingdom | 1 | 2010 | 260 | 0.020 |
Why?
| Amino Acid Sequence | 1 | 2013 | 2123 | 0.020 |
Why?
| Observer Variation | 1 | 2010 | 314 | 0.020 |
Why?
| Hypoglycemia | 1 | 2013 | 406 | 0.020 |
Why?
| Pilot Projects | 1 | 2013 | 1477 | 0.020 |
Why?
| Diagnostic Errors | 1 | 2010 | 171 | 0.020 |
Why?
| Genotype | 1 | 2014 | 1943 | 0.020 |
Why?
| Hepatitis C | 1 | 2011 | 226 | 0.020 |
Why?
| Guidelines as Topic | 1 | 2010 | 273 | 0.020 |
Why?
| Dopamine Antagonists | 1 | 2008 | 22 | 0.020 |
Why?
| Data Interpretation, Statistical | 1 | 2010 | 345 | 0.020 |
Why?
| Sex Factors | 2 | 2009 | 1860 | 0.020 |
Why?
| Interviews as Topic | 1 | 2010 | 601 | 0.020 |
Why?
| Evidence-Based Medicine | 1 | 2011 | 731 | 0.020 |
Why?
| Blood Pressure | 2 | 2004 | 1713 | 0.020 |
Why?
| Attitude of Health Personnel | 1 | 2014 | 1012 | 0.020 |
Why?
| Patient Care Team | 1 | 2011 | 520 | 0.020 |
Why?
| Burn Units | 1 | 2007 | 26 | 0.020 |
Why?
| Anxiety | 1 | 2013 | 888 | 0.020 |
Why?
| Cellulitis | 1 | 2007 | 48 | 0.020 |
Why?
| Renal Insufficiency, Chronic | 1 | 2013 | 602 | 0.020 |
Why?
| Hospitals, University | 1 | 2007 | 183 | 0.020 |
Why?
| Seasons | 1 | 1988 | 468 | 0.020 |
Why?
| Colistin | 1 | 2005 | 10 | 0.020 |
Why?
| Polymyxin B | 1 | 2005 | 22 | 0.020 |
Why?
| Antigens, CD34 | 1 | 2006 | 98 | 0.020 |
Why?
| Antidiuretic Agents | 1 | 2005 | 7 | 0.020 |
Why?
| Cell Count | 1 | 2006 | 319 | 0.020 |
Why?
| Depression | 1 | 2013 | 1190 | 0.020 |
Why?
| Follow-Up Studies | 1 | 2014 | 4768 | 0.020 |
Why?
| Ceftazidime | 1 | 2004 | 5 | 0.020 |
Why?
| beta-Lactam Resistance | 1 | 2004 | 7 | 0.020 |
Why?
| Predictive Value of Tests | 1 | 2010 | 1947 | 0.020 |
Why?
| Methotrexate | 1 | 2006 | 227 | 0.020 |
Why?
| Product Surveillance, Postmarketing | 1 | 2004 | 70 | 0.020 |
Why?
| Transplantation, Homologous | 1 | 2006 | 413 | 0.020 |
Why?
| Tobramycin | 1 | 2004 | 48 | 0.020 |
Why?
| Sentinel Surveillance | 1 | 2004 | 39 | 0.020 |
Why?
| Urine | 1 | 2004 | 65 | 0.020 |
Why?
| Hypertension | 1 | 2013 | 1245 | 0.010 |
Why?
| Hospitals, Teaching | 1 | 2004 | 114 | 0.010 |
Why?
| Hospitals, Urban | 1 | 2004 | 140 | 0.010 |
Why?
| Disease Models, Animal | 1 | 1993 | 3799 | 0.010 |
Why?
| Biomarkers | 1 | 2014 | 3662 | 0.010 |
Why?
| Emergency Service, Hospital | 1 | 2014 | 1922 | 0.010 |
Why?
| Acute Disease | 1 | 2006 | 984 | 0.010 |
Why?
| Hospital Mortality | 1 | 2007 | 901 | 0.010 |
Why?
| Tablets | 1 | 2002 | 39 | 0.010 |
Why?
| Reproducibility of Results | 1 | 2010 | 2977 | 0.010 |
Why?
| Skin Diseases | 1 | 2004 | 171 | 0.010 |
Why?
| Intestinal Absorption | 1 | 2002 | 106 | 0.010 |
Why?
| Herpesvirus 4, Human | 1 | 2002 | 127 | 0.010 |
Why?
| Population Surveillance | 1 | 2004 | 439 | 0.010 |
Why?
| Physicians | 1 | 2010 | 824 | 0.010 |
Why?
| Coronary Thrombosis | 1 | 2001 | 27 | 0.010 |
Why?
| Dose-Response Relationship, Radiation | 1 | 2001 | 131 | 0.010 |
Why?
| Gamma Rays | 1 | 2001 | 53 | 0.010 |
Why?
| Radiotherapy Dosage | 1 | 2001 | 244 | 0.010 |
Why?
| Heart Rate | 1 | 2004 | 756 | 0.010 |
Why?
| Angioplasty, Balloon, Coronary | 1 | 2001 | 163 | 0.010 |
Why?
| Trigeminal Ganglion | 1 | 1999 | 22 | 0.010 |
Why?
| Inhibitory Concentration 50 | 1 | 1999 | 82 | 0.010 |
Why?
| Virus Shedding | 1 | 1999 | 47 | 0.010 |
Why?
| Glomerular Filtration Rate | 1 | 2003 | 697 | 0.010 |
Why?
| Virus Latency | 1 | 1999 | 80 | 0.010 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2013 | 2221 | 0.010 |
Why?
| Secondary Prevention | 1 | 2001 | 257 | 0.010 |
Why?
| Rabbits | 1 | 1999 | 808 | 0.010 |
Why?
| Homeostasis | 1 | 2002 | 596 | 0.010 |
Why?
| Combined Modality Therapy | 1 | 2001 | 1174 | 0.010 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2001 | 425 | 0.010 |
Why?
| Serum Albumin | 1 | 1996 | 151 | 0.010 |
Why?
| Elective Surgical Procedures | 1 | 1996 | 165 | 0.010 |
Why?
| Nymph | 1 | 1993 | 5 | 0.010 |
Why?
| Myocardial Infarction | 1 | 2001 | 1134 | 0.010 |
Why?
| Saliva | 1 | 1993 | 215 | 0.010 |
Why?
| Postoperative Complications | 1 | 1996 | 2301 | 0.000 |
Why?
|
|
Fish's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|